Oxycodone

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Oxycodone
   1. Pharmacist Assessment Report
   2. Oxycodone: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Oxycodone: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Oxycodone, so there is currently no new predicted indication. The drug’s recorded uses are listed below; in this case no known uses are recorded.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	0
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
12031F	Oxycodone BNM	Capsule containing oxycodone hydrochlori	Valid

Safety Considerations

• Knowledge-graph contraindication signals (from a drug-disease knowledge graph, not product label text): liver failure and liver disease, kidney disease, respiratory failure, epilepsy, hypothyroidism, inflammatory bowel disease, substance abuse/dependence, myocardial infarction, sudden cardiac arrest, heart conduction disease, hypotensive disorder, benign prostatic hyperplasia, gallbladder disease, and others.
• Drug Interactions (100 interactions recorded; examples of Major level): alvimopan, bupropion, aprepitant, morphine, dexamethasone, cimetidine, clarithromycin and clotrimazole. Moderate-level examples include hyoscyamine, loperamide, atropine, glycopyrronium and eluxadoline.
• Literature-reported risks: dependence, misuse, respiratory depression and sleep-disordered breathing, and augmentation or tolerance with long-term use.

Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---